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Background: The contribution of fibrinogen (FBN) to hemostasis acting on platelet aggregation 
and clot formation is well established. It has been suggested that FBN-coated liposomes could 
be useful in restoring hemostasis. In the present study, we evaluated the modifications induced 
by multilamellar raw liposomes (MLV) or fibrinogen-coated liposomes (MLV-FBN) on hemo-
static parameters.
Materials and methods: Different experimental settings using whole blood or thrombocy-
topenic blood were used. Thromboelastometry, aggregation studies, platelet function analyzer 
(PFA-100®) tests and studies under flow conditions were applied to detect the effect of MLV-
FBN on hemostatic parameters.
Results: The presence of MLV-FBN in whole blood modified its viscoelastic properties, pro-
longing clot formation time (CFT) (226.5 ± 26.1 mm versus 124.1 ± 9.4 mm; P , 0.01) but 
reducing clot firmness (45.4 ± 1.8 mm versus 35.5 ± 2.3 mm; P , 0.05). Under thrombocytopenic 
conditions, FIBTEM analysis revealed that MLV-FBN shortened clotting time (CT) compared 
to MLV (153.3 ± 2.8 s versus 128.0 ± 4.6 s; P , 0.05). Addition of either liposome decreased 
fibrin formation on the subendothelium (MLV 8.1% ± 4.7% and MLV-FBN 0.8% ± 0.5% versus 
control 36.4% ± 6.7%; P , 0.01), whereas only MLV-FBN significantly reduced fibrin deposition 
in thrombocytopenic blood (14.4% ± 6.3% versus control 34.5% ± 5.2%; P , 0.05). MLV-FBN 
inhibited aggregation induced by arachidonic acid (52.1% ± 8.1% versus 88.0% ± 2.1% in 
control; P , 0.01) and ristocetin (40.3% ± 8.8% versus 94.3% ± 1.1%; P , 0.005), but it did not 
modify closure times in PFA-100® studies. In perfusion experiments using whole blood, MLV 
and MLV-FBN decreased the covered surface (13.25% ± 2.4% and 9.85% ± 2.41%, respectively, 
versus control 22.0% ± 2.0%; P , 0.01) and the percentage of large aggregates (8.4% ± 2.3% 
and 3.3% ± 1.01%, respectively, versus control 14.6% ± 1.8%; P , 0.01).
Conclusion: Our results reveal that, in addition to the main contribution of fibrinogen to 
hemostasis, MLV-FBN inhibits platelet-mediated hemostasis and coagulation mechanisms.
Keywords: thrombocytopenia, hemostasis, fibrinogen, liposomes, procoagulant activity, 
fibrin
Introduction
Liposomes are widely implemented for therapeutic use as drug carriers, as well as 
in drug targeting and other pharmacological applications, including basic research 
and applied technology.1,2 In previous studies, our group demonstrated the devel-
opment of procoagulant activity in damaged vessels of synthetic phospholipids 
and liposomes,3,4 opening up new possibilities for using liposomes as platelet 
substitutes to improve hemostasis. Several groups have explored the use of modi-
fied liposomes and microcapsules as coagulants in order to improve hemostasis.3–9 
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Recently, the use of nanotechnological approaches to stop   
bleeding has been explored.10 In this context, the effects 
of prohemostatic molecules, such as clotting factors in 
liposomes, could provide many advantages in controlling 
hemorrhages.
Fibrinogen (FBN) is a 340 kDa protein that is present in 
plasma at a concentration of 2 to 3 mg/mL. It has two identi-
cal disulfide-linked subunits composed of three nonidentical 
polypeptide chains: Aα, Bβ, and γ. In addition, a γ ′ chain is 
found in approximately 10% of FBN molecules. The four 
carboxyl-terminal amino acids found in the γA chain are 
substituted by a highly anionic 20-amino acid sequence in 
the γ ′ chain.11 FBN plays an important role in blood coagu-
lation as the substrate for thrombin, which is the final step 
in the coagulation cascade that results in fibrin formation.12 
Moreover, FBN mediates platelet aggregation by binding and 
bridging glycoprotein IIb-IIIa (GPIIb-IIIa).13 Two regions of 
the FBN α chain that contain an arginine-glycine-aspartic 
acid motif, as well as the carboxyl-terminus of the FBN γ 
chain, represent potential binding sites for GPIIb-IIIa in the 
fibrinogen molecule.14,15
Thus, combining adequate sequences of adhesive pro-
teins in the correct conformation on the appropriate carrier 
could improve primary hemostasis without enhancing fibrin 
formation. In the present study, we explored the effects of 
both raw multilamellar liposomes (MLV) and fibrinogen-
coated liposomes (MLV-FBN) on platelet function by using 
different experimental approaches: platelet aggregation 
induced by different agonists; experiments under flow 
conditions using the platelet function analyzer PFA-100® 
(Siemens Healthcare Diagnostics, Deerfield, IL) device; and 
perfusion systems to evaluate platelet interaction and fibrin 
formation on the subendothelium. Moreover, viscoelastic 
properties and the quality of clot formation were tested by 
thromboelastometric techniques.
Materials and methods
Experimental design
The present study was designed to evaluate the possible 
effect of liposomes containing FBN on different hemostatic 
parameters. The activity of liposomes was evaluated using 
whole blood and mild thrombocytopenic blood (30,000 
platelets/µL) anticoagulated with low-molecular-weight 
heparin (LMWH) or citrate (19 mM), depending on the test 
used. Blood samples were incubated with MLV or MLV-FBN 
liposomes and the effects on the coagulation system, platelet 
activation, thrombus formation, and fibrin generation were 
assessed by different experimental settings.
Reagents
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (PE) 
and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-
N-[4-(p-maleimidophenyl)butyramide] (N-MPB-PE) were 
purchased from Avanti Polar Lipids (Alabaster, AL); 
1,2-dipalmitoyl-rac-glycero-3-phosphocholine (DPPC), 
cholesterol (CHOL), and FBN from human plasma 
protein  from  Sigma-Aldrich  (St  Louis,  MO);  and 
N-  succinimidyl-S-acetylthioacetate (SATA) from Pierce 
(Rockford, IL). The buffer used was 50 mM 4-(2-hydroxyethyl)-1- 
piperazine ethanesulphonic acid (HEPES), pH 7.5 (with 
and without 1 mM ethylenediaminetetraacetic acid for lipo-
somes with and without FBN). Other reagents used were 
of analytical grade. The water used was ultrapure (MilliQ 
reverse osmosis system; Millipore, Billerica, MA) with a 
  resistivity of 18.3 MΩ/cm. Arachidonic acid and ristocetin 
were purchased from Helena BioSciences Europe (Gateshead, 
UK), while collagen and adenosine diphosphate (ADP) were 
from Arkray Inc (Kyoto, Japan). ROTEM® reagents for the 
EXTEM and FIBTEM tests were from Pentapharm GmbH 
(Aesch, Switzerland).
Liposome preparation  
and characterization
Phospholipids  (DPPC:CHOL:N-MPB-PE  and 
DPPC:CHOL:PE at a molar ratio of 50:20:30) were dis-
solved in chloroform in a round-bottomed flask and dried 
in a rotary evaporator under reduced pressure at 50oC to 
form a thin film on the flask. The film was hydrated with 
a solution of 10 mM HEPES buffer (pH 7.4) and 145 mM 
NaCl to give a lipid concentration of 20 mM. Multilamellar 
liposomes were formed by constant vortexing for 4 minutes 
on a vortex mixer followed by sonication for 4 minutes in a 
Transsonic Digital T460/H bath sonicator (Elma®, Singen, 
Germany) to guarantee the complete suspension of lipids. 
Vesicle size, size distribution and ζ-potential were determined 
at 25oC by photon correlation spectroscopy and Doppler 
microelectrophoresis, using a Zetasizer Nano ZS90 (Malvern 
Instruments, Malvern, UK).16
Preparation of thiolated fibrinogen  
and coupling to liposomes
The procedure for thiolating proteins with SATA has been 
previously reported.17 The number of introduced thiol groups 
was assayed according to Ellman, using cysteine for the 
calibration curve.18 According to this assay, the number 
of introduced thiol groups (expressed as mol of SH/mol of 
FBN) was 1.6 ± 0.1.
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A volume of liposome suspension (DPPC: N-MPB-PE) 
was combined with an equal volume of fibrinogen solution. 
The resulting suspension was left to react overnight at room 
temperature while being centrifuged at 1,000 rpm.
The coupling reaction was stopped by adding 50 µL of 
N-ethylmaleimide (8 mM in HEPES buffer) and the liposomes 
were separated from free protein by two centrifugation steps 
in Optima L-100XP (Beckman-Coulter, Fullerton, CA) for 
40 minutes at 100,000 g and 7°C. Liposomes (with or with-
out FBM) were prepared in different batches. Measurements 
of size, ζ-potential, and amount of thiol groups introduced 
on the liposomal surface served as control parameters to 
ensure that the physicochemical properties were the same 
in all batches used.
Blood collection and preparation  
of thrombocytopenic blood
Blood was obtained from six healthy volunteers (4 males and 
2 females, with an age range from 20 to 65 years) who had not 
taken drugs affecting platelets or coagulation mechanisms in 
the previous 10 days. Prior to the study, our local institutional 
ethics committee approved the protocol, which conformed 
to the ethical guidelines of the Helsinki Declaration. Written 
informed consent was obtained from all subjects. Blood was 
anticoagulated with LMWH (Fragmin®; Pfizer Inc, New York, 
NY) at a final concentration of 20 U/mL. This concentration 
of LMWH allows the generation of thrombin when blood is 
exposed to a denuded vascular segment.19–22 Blood platelets 
and leukocytes were reduced by a filtration procedure,23 
using an RC100 filter (PALL Corp, Glen Cove, NY). The 
platelet number was adjusted to 30,000 platelets/µL, mix-
ing thrombocytopenic blood and whole blood. Before each 
experiment, samples were preincubated with liposomes 
coupled or uncoupled to FBN for 2 min at 37ºC. PFA-100® 
and aggregation experiments were performed with blood 
anticoagulated by citrate at a final concentration of 19 mM 
using standard laboratory procedures.
Thromboelastometric studies
To examine the kinetics and quality of clot formation, we used 
the ROTEM® thromboelastometry analyzer.24 The technique 
was performed according to the manufacturer’s instructions. 
We used two different tests: EXTEM and FIBTEM. In the 
EXTEM test, tissue factor (TF) is used as an activator and is 
sensitive to changes in the extrinsic pathway of coagulation, 
FBN and fibrin polymerization, and platelet function. In the 
FIBTEM test, platelet function is inhibited by the platelet 
inhibitor cytochalasin D. While the clots obtained in EXTEM 
were formed by platelets and fibrin, the clot obtained in the 
FIBTEM assay was primarily a fibrin clot.
The study was carried out with whole and thrombocy-
topenic blood (30,000 platelets/µL) using 300 µL of blood 
containing 10% liposomes coupled or uncoupled to FBN. 
Measurements were recorded for 30 minutes, while controls 
were performed simultaneously by adding 10% of the cor-
responding buffer to the blood.
The main effect of liposomes was measured during clot 
formation by the standard thrombelastometric parameters: 
clotting time (CT) is the period of time from the start of 
the analysis until the clot reached 2 mm in amplitude; clot 
formation time (CFT) is the period until 20 mm amplitude 
was reached; and clot firmness was measured at 10-minute 
intervals (A10).25 The CT and CFT, measured in seconds, 
indicate the dynamics of clot formation. The clot amplitude 
(mm) gives information about clot strength and stability, 
which largely depends on FBN and platelets.
Platelet aggregation
The experiments were performed in a four-channel 
aggregometer (APACT 4, Helena BioSciences) according to 
the classical turbidimetric technique.26 Aliquots of 450 µL 
of platelet-rich plasma were transferred to the aggregometer 
cuvette and activated with different agonists: arachidonic acid 
and ristocetin (Helena BioSciences) at a final concentration 
of 1.4 mM and 1 mg/mL, respectively, and collagen and ADP 
at a final concentration of 2.5 µg/mL and 2 µM, respectively. 
The values of maximal platelet aggregation were recorded 
and expressed as percentages.
PFA-100® studies
PFA-100® evaluates the hemostatic capacity of platelets as a 
function of their ability to occlude an aperture in a membrane 
coated with collagen and epinephrine (EPI) or collagen and 
ADP under high shear stress (5000 s–1).27 Normality values 
for closure times previously established for the PFA-100® in 
our laboratory were 113 ± 24 s (mean ± standard deviation 
(SD)) with cartridges containing collagen and epinephrin 
(COL-EPI) and 87 ± 18 s with cartridges containing collagen 
and adenosin diphosphate (COL-ADP).21 Aliquots of blood 
incubated with MLV or MLV-FBN were used to study 
potential changes in closure time.
Perfusion studies
Rabbit abdominal aortic segments were prepared and pro-
cessed as previously described.28 Everted segments were 
mounted on a rod and inserted into the annular chamber. 
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Two-mL aliquots of each liposome preparation were added 
to the blood samples. Control perfusions were carried out by 
adding equivalent amounts of the buffer used in the phos-
pholipid preparations. The perfusates, with a total volume 
of 20 mL, were incubated at a constant temperature of 37°C 
for 2 minutes before starting the perfusion. Perfusions were 
conducted in annular chambers according to the method 
previously described.3,4,28 Blood was recirculated through the 
chamber for 10 minutes at 37°C at a shear rate of 250 s–1, 
using a peristaltic pump. This low shear rate facilitates fibrin 
deposition onto the subendothelium.
At the end of the perfusion, vessel segments were 
histologically processed. Platelet interaction and fibrin 
deposition onto perfused subendothelium were analyzed 
morphometrically as previously described. Platelet interaction 
was expressed as the percentage of covered surface by 
platelets and the percentage of big platelet aggregates 
(.5 µm) classified as % thrombi (% T). The presence of 
fibrin was expressed as a percentage of fibrin.20,29,30
Data analysis
Results are expressed as mean ± standard error of the mean 
(SEM). The number of experiments for each preparation was 
at least n = 6. Student’s t-test for paired data was used to 
compare differences between the control and the treated 
samples. The level of statistical significance was established 
at P , 0.05.
Results
Liposome characterization
The average size of liposomes, irrespective of the presence 
of FBN, ranged from 0.8 to 1.4 µm, and their polydispersity 
was close to 0.80. The incubation ratio of SATA to FBN of 
10 (molar ratio) resulted in the introduction of 1.5 to 1.7 mol 
of thiol groups/mol of FBN. FBN was coupled at a ratio of 
33 to 53 µg of FBN per µmol of phospholipid in the different 
FBN-MLV batches tested.
Measurements of the ζ-potential of raw liposomes in 
water afforded an average value of –8 mV , whereas after the 
coupling of fibrinogen, this value increased to –75 mV .
Effect of liposome preparation  
on hemostatic parameters
Thromboelastometric studies
The addition of MLV-FBN to whole blood did not modify the 
CT in comparison with the control in the EXTEM analysis. 
However, the presence of MLV-FBN led to a significant 
increase in the CFT (226.5 s ± 26.13 versus 124.17 s ± 9.46; 
P , 0.01), indicating a certain inhibition of clot formation. 
Moreover, MLV-FBN reduced clot firmness, measured 
as A10, with respect to control (35.50 ± 2.38 mm versus 
45.40 ± 1.82 mm; P , 0.05). These results are summarized 
in Figure 1. No differences were observed when the experi-
ments were performed using thrombocytopenic blood.
The analysis of parameters using the FIBTEM tests 
indicated that the addition of MLV-FBN to whole blood did 
not induce differences compared to the control. However, in 
experiments performed with thrombocytopenic blood, MLV-
FBN decreased the CT with respect to MLV (153.33 ± 2.82 
versus 128.00 ± 4.62; P , 0.05), whereas no differences were 
found between MLV-FBN and control (Figure 1).
As expected, the results using whole blood in the EXTEM 
test showed a reduction in clot formation and clot firmness. 
This test reflected the role of platelets and coagulation pro-
cesses in hemostasis. In contrast, results obtained with the 
FIBTEM tests, which eliminated platelet function, showed 
significant differences in thrombocytopenic blood.
Platelet aggregation studies
MLV modified aggregation profiles only when arachi-
donic acid was used as an agonist (50.9% ± 7.9% versus 
88.0% ± 2.1% in control; P , 0.01). Interestingly, MLV-
FBN also inhibited aggregation induced by arachidonic acid 
(52.1% ± 8.1% versus 88.0% ± 2.1% in control; P , 0.01) 
and ristocetin (16.7 ± 3.2 versus 68.3% ± 5.8%; P , 0.01). 
Aggregations induced by ADP and collagen were not modi-
fied by either MLV or MLV-FBN. However, we observed a 
reduction in the maximal aggregation induced by ADP in the 
case of MLV-FBN, but this was not statistically significant. 
These results are summarized in Figure 2.
PFA-100® studies
The addition of liposomes to whole blood did not statistically 
modify closure times in the PFA-100® device. COL-EPI car-
tridges showed values of 171 ± 48.1 s for MLV , 194 ± 27.3 s 
for MLV-FBN, and 184 ± 27.4 s for control. Results using 
COL-ADP cartridges were 113.5 s ± 21.6 s for MLV, 
124.3 ± 20.5 s for MLV-FBN, and 95 ± 16.9 s for control.
Perfusion experiments
Perfusions with whole blood resulted in a platelet coverage 
surface of 22.01% ± 2.05%. Addition of MLV and MLV-FBN 
to whole blood samples decreased the coverage surface of 
platelets (13.25% ± 2.4% and 9.85% ± 2.41%, respectively, 
versus 22.01% ± 2.05%; P , 0.01). A more detailed analysis 
of platelet interaction also showed a decrease in the presence 
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of large aggregates measured as % T (8.44% ± 2.33% and 
3.36% ± 1.01%, respectively, versus 14.64% ± 1.89% in control 
experiments; P , 0.01). Moreover, a significant decrease 
in fibrin deposition was observed when liposomes were 
present in perfusates (MLV 8.12% ± 4.73% and MLV-FBN 
0.84% ± 0.52% versus control 36.48% ± 6.76%; P , 0.01). 
Representative microscopic fields are shown in Figure 3.
Experiments performed under conditions of moderate 
thrombocytopenia revealed that the presence of liposomes 
resulted in a significant reduction (P , 0.05) of the percent-
age of covered surface by platelets (MLV 7.30% ± 1.17% and 
MLV-FBN 6.99% ± 0.94% versus 12.50% ± 1.31% in throm-
bocytopenic blood; P , 0.05). MLV did not modify fibrin 
deposition on the subendothelium (34.58% ± 5.21%), but there 
was a significant decrease in fibrin deposition after the addition 
of MLV-FBN to thrombocytopenic blood (14.47% ± 6.34%; 
P , 0.05). These results are summarized in Figure 4.
Discussion
The present study focused on the preparation of FBN-coated 
liposomes in order to improve hemostatic mechanisms, 
such as platelet reactivity and coagulation mechanisms. 
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Figure 1 Thromboelastometric results of EXTEM- (A–C) and FIBTEM (D and E) derived parameters (CT and CFT expressed in s, and A10 in mm). Experiments were 
performed in whole blood (WB) and thrombocytopenic blood (TPN) following in vitro addition of MLV and MLV-FBN.
Notes: Data presented as mean ± SEM, n = 6. *MLV-FBN versus control P , 0.01; #MLV-FBN versus MLV liposomes P , 0.01.
Abbreviations: CT, clotting time; CFT, clot formation time; CON, control; MLV, raw multilamellar liposomes; MLV-FBN, fibrinogen-coated liposomes; SEM, standard 
error of the mean.
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In recent years, several groups have explored the use of 
modified liposomes and microcapsules as coagulants to 
improve hemostasis.5–9,31,32 Our group demonstrated that 
raw preparations of phospholipids were able to activate the 
coagulation system and promote fibrin formation on dam-
aged vascular surfaces under thrombopenic conditions.3 
A reduction of platelet counts is quite common in oncohe-
matological patients who exhibit hemorrhagic episodes that 
sometimes may require platelet transfusion. Originally, the 
present study was designed to evaluate the possible effect 
of FBN-containing liposomes as a prohemostatic strategy 
in different conditions, such as normal platelet counts and 
thrombocytopenic conditions, in order to mimic patients 
potentially requiring platelet transfusion.
Under our experimental conditions, FBN-coated lipo-
somes modified blood coagulation parameters, as indicated 
by the thromboelastometric and fibrin deposition results. In 
the FIBTEM thromboelastometric studies, in which platelets 
were inhibited, MLV-FBN reduced the CT in thrombocy-
topenic blood, indicating a positive effect on the coagula-
tion mechanism. Interestingly, studies using EXTEM tests 
on whole blood, when both platelets and the coagulation 
mechanism are active, have demonstrated a partial inhibi-
tion of overall hemostatic parameters that includes a reduc-
tion in CFT and clot firmness. Moreover, our results of the 
experiments under moderate flow conditions indicate that 
MLV-FBN induced lower clotting activity, as demonstrated 
by a decrease in fibrin deposition on the subendothelium. 
Furthermore, MLV-FBN acted on primary hemostasis, 
as demonstrated by decreased platelet interactions in the 
perfusion experiments performed at a moderate shear rate. 
However, no differences were observed at a high shear rate, 
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Figure 2 Bar diagram summarizing changes in platelet aggregation induced by different agonists (AA, ADP, COL, and RIST) in samples treated with MLV or MLV-FBN. Results 
are expressed as mean ± SEM; n = 6; *P , 0.05; **P , 0.01.
Abbreviations: AA, arachidonic acid; ADP, adenosine diphosphate; COL, collagen; RIST, ristocetin; MLV, raw multilamellar liposomes; MLV-FBN, fibrinogen-coated 
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Figure 3 Light micrographs representative of changes induced by MLV-FBN in platelet interaction (p) and fibrin deposition (f) on the subendothelium observed in perfusions 
using whole blood (WB) and thrombocytopenic blood (TPN). (A) WB control; (B) TPN control; (C) WB + MLV-FBN; (D) TPN + MLV-FBN.
Abbreviations: MLV, raw multilamellar liposomes; MLV-FBN, fibrinogen-coated liposomes.
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as shown by the closure time obtained with the PFA-100®. 
In fact, it is well established that the shear rate has a role 
in platelet adhesion and fibrin formation. Under high shear 
rates, platelet interactions predominate over fibrin formation, 
whereas under moderate and low shear rates, coagulation 
mechanisms prevail over platelet interactions.33–35 We also 
observed an inhibition in the aggregation profiles induced 
by ristocetin and arachidonic acid. In the presence of lipo-
somes, this reduction could be explained by a direct effect 
of MLV-FBN on the GpIbα complex32 in the ristocetin assay 
and by the phospholipidic composition of the liposomes. 
Indeed, it has been shown conclusively that the net charge 
of liposomes and the firmness of the membranes determine 
the effect on hemostasis.4,32,36
Although the antihemostatic activity observed in our 
experiments with FBN-coated liposomes cannot be ascribed 
to the γ ′ chain of FBN, our results (reduced thrombin genera-
tion, inhibition of ristocetin-induced aggregation, decrease 
in fibrin density and inhibition of thrombus formation) 
show behavior similar to that described for the γ ′ chain.11,37 
This could be explained by a global negative charge in our 
liposomes17 and the use of thiolated FBN during the binding 
procedure, which could induce residue sulfation and gener-
ate conformational changes in the molecule similar to those 
observed in the γ ′ chain. Interestingly, the effect of MLV-
FBN suggests that with a high number of platelets, FBN acts 
mainly in primary hemostasis, whereas its participation in 
coagulation is moderate.
Inconsistent effects of FBN have been described to date, 
probably because FBN can undergo several posttranslational 
modifications, such as glycosylation, glycation, nitration, 
oxidation, sulfation, phosphorylation and proteolytic degra-
dation, and genetic differences among individuals.32 In fact, 
contradictory results in studies on FBN binding to liposomes 
have been published. Whereas some studies show that con-
ventional approaches to binding proteins to liposomes do not 
work effectively with FBN to provide a final product with 
hemostatic properties,38 others demonstrate that the binding 
to liposomes of the dodecapeptide H12, corresponding to 
a fibrinogen γ-chain carboxy-terminal sequence, yields a 
product with demonstrated hemostatic activity.31
The biological function of FBN can be modified by 
changes in protein folding.39 It is accepted that structural 
features of fibrinogen are related to multiple biological 
functions, including binding to thrombin, fibrinolysis, regu-
lation of FXIII activity, and interactions with blood cells, 
such as platelets and leukocytes. Residues A414 to L427 
of the γ ′ chain have been reported to play a central role in 
thrombin binding because of their overall negative charge, 
which disrupts the platelet binding domain in the γA chain 
and introduces a binding site for zymogen factor XIII and 
thrombin.10–13 Moreover, the sulfation of residues Y418 
and Y422 further enhances thrombin binding by increas-
ing the net charge and inhibiting thrombin activity.32,40 On 
the other hand, γXL sites in FBN are also involved in the 
binding to FXIII and to the platelet integrin GPIIb/IIIa. It 
is not surprizing that when chemical modification occurs, 
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Figure 4 Bar diagram summarizing changes in platelet interaction in samples treated 
with MLV or MLV-FBN.
Notes: Results are expressed as % covered surface by platelets, % of large aggregates 
(thrombus), and % of fibrin deposition on the subendothelium. Mean ± SEM; n = 6. 
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fibrinogen-coated liposomes; SEM, standard error of the mean.
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the liposomalization of FBN gives liposomes the ability 
to bind to the GPIIb/IIIa of platelets, thus competitively 
inhibiting the formation of platelet aggregates. According 
to Sivaraman and Latour,39 the conformation of FBN is 
the critical determinant of platelet adhesion. Adsorption-
induced unfolding can expose two distinctly different types 
of platelet-binding sites in FBN: one induces platelet adhe-
sion alone, and the other induces both platelet adhesion and 
activation.11,29,41
The present study, in contrast to its initial purpose, 
offers the possibility of developing new clinical strategies 
for regulating arterial or venous thrombosis based on the 
use of liposomes. Our data suggest that the antihemostatic 
effect observed on liposomes is probably related to the 
conformational structure adopted by the FBN after binding 
to the liposome. These changes seem to play an important 
role not only in blood clot formation and stabilization, but 
also in primary hemostasis. Future investigations will need 
to address how the binding procedure may interfere with 
hemostasis.
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